Ab­b­Vie drops Cari­bou part­ner­ship on gene-edit­ed CAR-T ther­a­py

Ab­b­Vie has ter­mi­nat­ed its col­lab­o­ra­tion with Cari­bou Bio­sciences to de­vel­op two off-the-shelf CAR-T ther­a­pies, Cari­bou dis­closed Tues­day af­ter­noon.

Ab­b­Vie paid the Jen­nifer Doud­na-found­ed start­up $40 mil­lion up­front in 2021, and promised up to $300 mil­lion for two CAR-T ther­a­pies with undis­closed tar­gets. Cari­bou us­es a hy­brid gene edit­ing tech­nol­o­gy it calls chRD­NA (pro­nounced “chardon­nay”) to en­gi­neer donor cells in­to CAR-T ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.